

P&T Motion History
Diabetes – SGLT2 Inhibitors

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
<p>canagliflozin canagliflozin + metformin canagliflozin + metformin ER dapagliflozin dapagliflozin + saxagliptin dapagliflozin + metformin ER empagliflozin empagliflozin + metformin empagliflozin + metformin ER empagliflozin + linagliptin ertugliflozin ertugliflozin + metformin</p>	<p>After considering the evidence of safety, efficacy and special populations for the treatment of diabetes, I move that canagliflozin, empagliflozin, dapagliflozin and all combinations in this sub-class are safe and efficacious for the treatment of their approved indications.</p> <p>SGLT-2 Inhibitors can be subject to therapeutic interchange in the Washington preferred drug list. Therapeutic interchange is allowed only within each diabetes sub-class.</p> <p>At least one drug with cardiovascular benefits needs to be preferred on the PDL for patients with proven cardiovascular disease.</p> <p>Motion: Schwilke 2nd: Storhaug</p>	<p>June 15, 2022</p>	<p>Yes Schwilke Park</p>	<p>Yes Beste MacKay</p>	<p>Passed unanimous</p>